Bermudez, Luiz E <br/><br/>
SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Sep 2004 
 - 3556-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0066-4804 
<br/><br/><label>Standard No.: </label>10.1128/AAC.48.9.3556-3558.2004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Anti-Bacterial Agents--adverse effects<br/>Aza Compounds--adverse effects<br/>Colony Count, Microbial<br/>Drug Interactions<br/>Drug Therapy, Combination<br/>Female<br/>Fluoroquinolones<br/>Liver--microbiology<br/>Mefloquine--adverse effects<br/>Mice<br/>Mice, Inbred C57BL<br/>Moxifloxacin<br/>Mycobacterium avium-intracellulare Infection--drug therapy<br/>Quinolines--adverse effects<br/>Spleen--microbiology<br/>Thioacetazone--adverse effects